Skip to main content
SpringerLink
Log in

New Medical Strategies: The Role of Oncologist in an MDT

  • Chapter
  • First Online:
Multidisciplinary Management of Prostate Cancer

  • 909 Accesses

Abstract

Prostate cancer that has escaped the hormonal manipulation has been regarded long time as a difficult-to-treat disease. Docetaxel-based chemotherapy has been deemed for years the only active treatment in patients with progressing prostate cancer while on hormonotherapy. However over the last years, a better understanding of the molecular biology of prostate cancer has made possible a crucial shift from the paradigm of “hormone refractory” prostate cancer into “castration-resistant” prostate cancer. This new perspective has been recently translated into clinical practice and drugs such as abiraterone acetate, cabazitaxel, and MDV-3100 have all demonstrated improvement of overall survival (OS) in patients with castration-resistant prostate cancer; hence, they are now available for the management of this disease. Nevertheless, prostate cancer is triggered by multiple molecular drivers and research is oriented to target the multiple pathways involved in the development and progression of castration-resistant prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10(10):981–991

    Article  PubMed Central  PubMed  Google Scholar 

  2. Holzbeierlein J, Lal P, LaTulippe E et al (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164(1):217–227

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042

    Article  CAS  PubMed  Google Scholar 

  4. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt TJ (1999) Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Syst Rev (2):CD001526. doi:10.1002/14651858.CD001526.5

  5. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet 375(9724):1437–1446. doi:10.1016/S0140-6736 (10) 60172-9

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67(10):5033–5041

    Article  CAS  PubMed  Google Scholar 

  7. Bedoya D, Mitsiades N (2012) Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev Anticancer Ther 12(1):1–3

    Article  CAS  PubMed  Google Scholar 

  8. Logothetis CJ, Gallick GE, Maity SN (2013) Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer discov 3(8):849–861. doi:10.1158/2159-8290.CD-12-0460

    Article  CAS  PubMed  Google Scholar 

  9. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 17(7–8):657–664

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Haapala K, Hyytinen ER, Roiha M, Laurila M et al (2001) Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 81:1647–1651

    Article  CAS  PubMed  Google Scholar 

  11. Gottlieb B, Beitel LK, Wu JH, Trifiro M (2004) The androgen receptor gene mutations database (ARDB). Hum Mutat 23:527–533

    Article  CAS  PubMed  Google Scholar 

  12. Koochekpour S (2010) Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 12(5):639–657. doi:10.1038/aja.2010.89

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Tsao C-K, Galsky MD, Small AC et al (2012) Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int 110(11):1580–1588. doi:10.1111/j.1464-410X.2012.11445.x

    Article  PubMed  Google Scholar 

  15. Kanthoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of cancer and leukemia group B 9182 Study. J Clin Oncol 17:2506–2513

    Google Scholar 

  16. Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 14:1756–1764

    CAS  PubMed  Google Scholar 

  17. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  CAS  PubMed  Google Scholar 

  18. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187

    Article  CAS  PubMed  Google Scholar 

  19. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  20. Kuroda K, Liu H, Kim S et al (2009) Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 69:1579–1585

    Article  CAS  PubMed  Google Scholar 

  21. Gan L, Chen S, Wang Y et al (2009) Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 69:8386

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Sanofi-Aventis (2010) Jevtana (cabazitaxel) injection prescribing information. Sanofi-Aventis, Bridgewater, NJ

    Google Scholar 

  23. Attard G, Greystoke A, Kaye S, de Bono J (2006) Update on tubulin binding agents. Pathol Biol 54:72–84

    Article  CAS  PubMed  Google Scholar 

  24. Aller AW, Kraus LA, Bissery MC (2000) In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines. Proc Am Assoc Cancer Res 41:303, abstr 1923

    Google Scholar 

  25. Bissery MC, Bouchard H, Riou JF et al (2000) Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res 41:214, abstr 1364

    Google Scholar 

  26. Oudard S (2011) TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 7:497–506

    Article  CAS  PubMed  Google Scholar 

  27. Bahl A, Oudard S, Tombal B et al (2013) Impact of cabazitaxel on 2-year survival and palliation of tumor-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24(9):2402–2408. doi:10.1093/annonc/mdt194

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. de Bono JS, Sartor O (2011) Cabazitaxel for castration-resistant prostate cancer-Authors’ reply (letter). Lancet 377:122–123

    Article  Google Scholar 

  29. Bahl A, Masson S, Birtle A et al (2013) Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev 1:170–177. doi:10.1016/j.ctrv.2013.06.008

    Google Scholar 

  30. Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28):4563–4571. doi:10.1200/JCO.2007.15.9749

    Article  CAS  PubMed  Google Scholar 

  31. Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992

    Article  CAS  PubMed  Google Scholar 

  32. Attard G, Reid AH, A’Hern R et al (2009) Selective inhibition of CYP17 with abir-aterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742–3748

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Ryan CJ, Smith MR, Fong L et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481–1488

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Ryan CJ, Shah S, Efstathiou E et al (2011) Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17:4854–4861

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Ryan CJ, Smith MR, De Bono JS et al (2012) Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Proc Am Soc Clin Oncol 30(suppl), abstr LBA4518

    Google Scholar 

  36. Ryan C (2010) Abiraterone in prostate cancer. Clin Adv Hematol Oncol 8:761–762

    PubMed  Google Scholar 

  37. Sartor O (2011) Combination therapy: abiraterone prolongs survival in metastatic prostate cancer. Nat Rev Clin Oncol 8:515–516

    Article  CAS  PubMed  Google Scholar 

  38. Pezaro CJ, Mukherji D, De Bono JS (2012) Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. Drug Discov Today 17(5–6):221–226. doi:10.1016/j.drudis.2011.12.012

    Article  CAS  PubMed  Google Scholar 

  39. Handratta VD, Vasaitis TS, Njar VC et al (2005) Novel C- 17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 48:2972–2984. doi:10.1021/jm040202w

    Article  CAS  PubMed  Google Scholar 

  40. Vasaitis T, Belosay A, Schayowitz A et al (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H -benzimidazole-1-yl) androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7:2348–2357. doi:10.1158/1535-7163.MCT-08-0230

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Montgomery RB, Eisenberger MA, Rettig M et al (2012) Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol 30(Suppl), abstr 4665

    Google Scholar 

  42. Hara T, Kouno J, Kaku T et al (2013) Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. J Steroid Biochem Mol Biol 134:80–91. doi:10.1016/j. jsbmb.2012.10.020

    Article  CAS  PubMed  Google Scholar 

  43. Dreicer R, Agus DB, MacVicar GR et al (2010) Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study [abstr 3084]. J Clin Oncol 28(15 suppl):254s

    Google Scholar 

  44. Jung ME, Ouk S, Yoo D et al (2010) Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 53:2779–2796

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Rathkopf DE, Morris MJ, Fox JJ et al (2013) Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 31(28):3525–3530. doi:10.1200/JCO.2013.50.1684

    Article  CAS  PubMed  Google Scholar 

  46. Bianchini D, Zivi A, Sandhu S, De Bono JS (2010) Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann Oncol 21(Suppl 7):vii43–vii55. doi:10.1093/annonc/mdq369

    PubMed  Google Scholar 

  47. Graddis TJ, McMahan CJ, Tamman J et al (2011) Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol 4(3):295–306

    PubMed Central  PubMed  Google Scholar 

  48. Sims RB (2012) Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30(29):4394–4397. doi:10.1016/j.vaccine.2011.11.058

    Article  CAS  PubMed  Google Scholar 

  49. Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094

    Article  CAS  PubMed  Google Scholar 

  50. Higano CS, Schellhammer PF, Small EJ (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16):3670–3679. doi:10.1002/cncr.24429

    Article  CAS  PubMed  Google Scholar 

  51. Kantoff PW, Higano CS, Shore ND, IMPACT Study Investigators et al (2010) Sipuleucel-T immunotherapy for castrate-resistant prostate cancer. N Engl J Med 363(5):411–422

    Article  CAS  PubMed  Google Scholar 

  52. Plosker GL (2011) Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs 71(1):101–108. doi:10.2165/11206840-000000000-00000

    Article  CAS  PubMed  Google Scholar 

  53. Di Paola RS, Plante M, Kaufman H et al (2006) A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 4:1

    Article  Google Scholar 

  54. DiPaola RS, Chen Y, Bubley GJ et al (2009) A phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802. In: Genitourinary cancers symposium 2009, abstr 108

    Google Scholar 

  55. Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099–1105, PubMed: 20100959

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Gulley JL, Arlen PM, Madan RA et al (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59:663–674, PubMed: 19890632

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Bilusic M, Gulley J, Heery C et al (2011) A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC) [abstr]. J Clin Oncol 29(7S):163

    Google Scholar 

  58. Madan RA, Mohebtash M, Arlen PM et al (2010) Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC): a double-blinded randomized phase I/II study. In: Program and abstracts of the 2010 American Society of Clinical Oncology Genitourinary Cancers symposium, San Francisco, CA, 5–7 March 2010. Abstract

    Google Scholar 

  59. Tollefson MK, Karnes RJ, Thompson RH et al (2010) A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. In: Program and abstracts of the 2010 American Society of Clinical Oncology Genitourinary Cancers symposium, San Francisco, CA, 5–7 March 2010, abstr 168

    Google Scholar 

  60. Olsson A, Björk A, Vallon-Christersson J et al (2010) Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 9:107

    Article  PubMed Central  PubMed  Google Scholar 

  61. Jennbacken K, Welen K, Olsson A et al (2012) Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate 72(8):913–924

    Article  CAS  PubMed  Google Scholar 

  62. Scher HI, Halabi S, Tannock I, Prostate Cancer Clinical Trials Working Group et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159

    Article  PubMed  Google Scholar 

  63. Pili R, Häggman M, Stadler WM et al (2011) Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29(30):4022–4028

    Article  CAS  PubMed  Google Scholar 

  64. Luo FR, Barrett YC, Yang Z et al (2008) Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 62:1065–1074, PubMed: 18301894

    Article  CAS  PubMed  Google Scholar 

  65. Yu EY, Massard C, Gross ME, Carducci MA et al (2011) Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77(5):1166–1171. doi:10.1016/j.urology.2011.01.006

    Article  PubMed Central  PubMed  Google Scholar 

  66. Araujo JC, Mathew P, Armstrong AJ et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 118(1):63–71. doi:10.1002/cncr.26204

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Araujo JC Trudel GC, Fred Saad et al (2013) Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. J Clin Oncol 31(suppl 6), abstr LBA8

    Google Scholar 

  68. Smith DC, Smith MR, Sweeney C et al (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31(4):412–419. doi:10.1200/JCO.2012.45.0494

    Article  CAS  PubMed  Google Scholar 

  69. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134. doi:10.1056/NEJMoa0900212

    Article  CAS  PubMed  Google Scholar 

  70. Sandhu SK, Schelman WR, Wilding G et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882–892. doi:10.1016/S1470-2045(13)70240-7

    Article  CAS  PubMed  Google Scholar 

  71. Zellweger T, Miyake H, Cooper S et al (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298:934–940

    CAS  PubMed  Google Scholar 

  72. Saad F, Hotte S, North S et al (2011) Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17(17):5765–5773. doi:10.1158/1078-0432.CCR-11-0859

    Article  CAS  PubMed  Google Scholar 

  73. Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28(27):4247–4254. doi:10.1200/JCO.2009.26.8771

    Article  CAS  PubMed  Google Scholar 

  74. Lamoureux F, Thomas C, Yin MJ et al (2011) Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 71(17):5838–5849. doi:10.1158/0008-5472.CAN-11-0994

    Article  CAS  PubMed  Google Scholar 

  75. Chi K, Yu EY, Ellard S et al (2012) A randomized phase II study of OGX-427 plus prednisone (P) vs. P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). Ann Oncol 23, abstr 900PD

    Google Scholar 

  76. MacVicar GR, Hussain MH (2013) Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 25(3):252–260. doi:10.1097/CCO.0b013e32835ff161

    CAS  PubMed  Google Scholar 

  77. Oh WK, Galsky MD, Stadler WM et al (2011) Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 78(3):626–630. doi:10.1016/j.urology.2011.04.041

    Article  PubMed Central  PubMed  Google Scholar 

  78. Heath EI et al (2005) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4:138–141

    Article  CAS  PubMed  Google Scholar 

  79. Heath EI et al (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14:7940–7946

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Bianchini D, Omlin AG, Pezaro CJ et al (2013) First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 31(suppl), abstr 5052

    Google Scholar 

  81. Vapiwala N, Glatstein E (2003) Fighting prostate cancer with radium-223—not your Madame’s isotope. N Engl J Med 369(3):276–278

    Article  Google Scholar 

  82. Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223. doi:10.1056/NEJMoa1213755

    Article  CAS  PubMed  Google Scholar 

  83. Loddick SA, Ross SJ, Andrew GT et al (2013) AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther 12:1715–1727

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  84. Omlin AG, Jones RJ, van der Noll R et al (2013) A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 31(suppl), abstr 4511

    Google Scholar 

  85. Smith MR (2004) The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology 18:21–25, 85

    PubMed  Google Scholar 

  86. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882

    Article  CAS  PubMed  Google Scholar 

  87. Smith MR, Egerdie B, Hernández Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755. doi:10.1056/NEJMoa0809003

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  88. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 377:813–822

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Cookson MS, Roth BJ, Dahm P et al (2013) Castration-resistant prostate cancer: AUA guideline. J Urol 190(2):429–438. doi:10.1016/j.juro.2013.05.005

    PubMed  Google Scholar 

  90. Mohler JL, Kantoff PW, Armstrong AJ (2013) Prostate cancer, version 1.2014. J Natl Compr Cancr Netw 11(12):1471–1479

    CAS  Google Scholar 

  91. Horwich A, Parker C, De Reijke T, Kataja V (2013) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:1–9. doi:10.1093/annonc/mdt208

    Google Scholar 

  92. Zhang TY, Agarwal N, Sonpavde G (2013) Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep 14(3):174–183. doi:10.1007/s11934-013-0322-0

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University Sapienza Rome, Viale del Policlinico 155, Rome, 00144, Italy

    Flavia Longo

Authors
  1. Flavia Longo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Flavia Longo .

Editor information

Editors and Affiliations

  1. Dept. of Urology, Sapienza University, Rome, Italy

    Vincenzo Gentile

  2. Department of Radiological Sciences, Oncology & Pathology, Sapienza University, Policlinico Umberto I, Latina, Italy

    Valeria Panebianco

  3. Dept. of Urology, Sapienza University, Rome, Italy

    Alessandro Sciarra

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Longo, F. (2014). New Medical Strategies: The Role of Oncologist in an MDT. In: Gentile, V., Panebianco, V., Sciarra, A. (eds) Multidisciplinary Management of Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-04385-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-04385-2_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-04384-5

  • Online ISBN: 978-3-319-04385-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation